EX VIVO PHOTODYNAMIC TREATMENT OF MALIGNANT LYMPHOID CELLS IN CHRONIC LYMPHOPROLIFERATIVE DISEASES
Keywords:
chronic lymphocytic leukemia, photodynamic treatment, aminolevulinic acid, etoposide, smudge cells, CD38, Zap-70.Abstract
Summary. Aim: To study the relations between the content of smudge cells in blood smears of the patients with Bcell chronic lymphocytic leukemia (B-CLL), the responsiveness of the malignant lymphoid cells to aminolevulinic
acid (ALA) mediated photodynamic (PD) treatment and
proapoptogenic effect of vepesid as well as the expression
CD38 and Zap-70 as the predicative markers of B-CLL.
Object and methods: the peripheral blood samples of patients with chronic lymphoproliferative diseases including B-CLL were examined (smears, cytospin specimens,
suspension of lymphoid cells). The immunocytochemical
techniques and morphological methods, PD treatment and
flow cytometry analysis of apoptosis were used. Results:
the malignant lymphoid cells of B-CLL patients are responsive to ALA-PD treatment ex vivo. The percentage of
B-CLL cell death caused by ALA-PD treatment exceeds
significantly that in the cases of polyclonal lymphocytosis. The responsiveness to ALA-PD treatment is inversely
related to the content of smudge cells in the smears. The
cell death caused by ALA-PD treatment does not correlate with the individual susceptibility to apoptosis induction by vepesid in primary B-CLL cell cultures. Conclusion: the results obtained demonstrate the high susceptibility of the malignant lymphoid cells of B-CLL patients
to ALA-PD treatment ex vivo.
References
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of
the World Health Organization classification of lymphoid neoplasms.
Blood 2016; 127 (20): 2375–90.
Mertens D, Stilgenbauer S. Prognostic and predictive factors in
patients with chronic lymphocytic leukemia: relevant in the era of novel
treatment approaches? J Clin Oncol 2014; 32 (9): 869–72.
Nabhan C, Rosen ST. Chronic lymphocytic leukemia: a clinical
review. JAMA 2014; 312 (21): 2265–76.
Dokic M, Urosevic I, Savic I, et al. A case of chronic lymphocytic leukaemia occurring during treatment of chronic myeloid leukaemia. Indian J Hematol Blood Transfus 2016; 32 (Suppl 1): 156–8.
Shvidel L, Berrebi A. Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare? Expert Rev Hematol 2016; 9 (3): 245–54.
Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol 2015; 90 (5):
–60.
Nowakowski GS, Hoyer JD, Shanafelt TD, et al. Percentage of
smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol 2009; 27 (11): 1844–9.
Johansson P, Eisele L, Klein-Hitpass L, et al. Percentage of
smudge cells determined on routine blood smears is a novel prognostic
factor in chronic lymphocytic leukemia. Leuk Res 2010; 34 (7): 892–8.
Gogia A, Raina V, Gupta R, et al. Prognostic and predictive significance of smudge cell percentage on routine blood smear in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2014; 14
(6): 514–7.
Rizzo D, Lotay A, Gachard N, et al. Very low levels of surface
CD45 reflect CLL cell fragility, are inversely correlated with trisomy
and are associated with increased treatment-free survival. Am J Hematol 2013; 88 (9): 747–53.
Gamaleia NF, Shishko ED, Gluzman DF, et al. Sensitivity of
normal and malignant human lymphocytes to 5-aminolevulinic acid-mediated photodynamic damage. Exp Oncol 2008; 30 (1): 65–9.
Ohgari Y, Nakayasu Y, Kitajima S, et al. Mechanisms involved in delta-aminolevulinic acid (ALA)-induced photosensitivity of tumor cells: relation of ferrochelatase and uptake of ALA
to the accumulation of protoporphyrin. Biochem Pharmacol 2005;
(1–2): 42–9.
Hrkal Z, Grebenová D, Cajthamlová H, et al. Use of photodynamic therapy for elimination of residual leukemic cells in autologous
transplants of hematopoietic progenitor cells. Cas Lek Cesk 2002; 141
(Suppl): 41–6 (in Czech).
Завелевич МП, Куява ЛМ, Фільченков ОО та ін. Відповідь
ex vivo злоякісних клітин пацієнтів із В-клітинним хронічним
лімфолейкозом на протипухлинні хіміопрепарати. Онкологія
; 16 (4): 262–8.
Castejón R, Yebra M, Citores MJ, et al. Drug induction apoptosis assay as predictive value of chemotherapy response in patients
with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2009;
(4): 593–603.
Глузман ДФ, Абраменко ИВ, Скляренко ЛМ и др. Диагностика лейкозов. Атлас и практическое руководство. К: Морион, 2000. 224 с.
Nicoletti I, Migliorati G, Pagliacci MC, et al. A rapid and
simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139
(2): 271–9.
Fumi M, Martins D, Pancione Y, et al. Automated quantification of apoptosis in B-cell chronic lymphoproliferative disorders: a prognostic variable obtained with the Cell-Dyn Sapphire
(Abbott) automated hematology analyzer. Int J Lab Hematol 2014;
(6): 628–35.
Szerafin L, Jakó J, Riskó F, Hevessy Z. The prognostic value
of smudge cells (Gumprecht shadows) in chronic lymphocytic leukaemia. Orv Hetil 2012; 153 (44): 1732–7.
Matos DM, Perini G, Kruzich C, et al. Smudge cells in peripheral blood smears did not differentiate chronic lymphocytic leukemia
from other B-cell chronic lymphoprolipherative diseases. Rev Brasil
Hematol Hemoter 2009; 31 (5): 333–6.
Wiggers TG, Westra G, Westers TM, et al. ZAP70 in B-CLL
cells related to the expression in NK cells is a surrogate marker for mutational status. Cytometry B Clin Cytom 2014; 86 (4): 280–7.
Nowakowski GS, Hoyer JD, Shanafelt TD, et al. Using smudge
cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clin
Proc 2007; 82 (4): 449–53.
Amr Z, Basma E. Peripheral blood smudge cells percentage in
de novo CLL: A comparison with other established laboratory prognostic markers. Life Sci J 2011; 8 (4): 239–44.
Herishanu Y, Kay S, Joffe E, et al. Integration of automated morphological features resolves a distinct group of atypical chronic lymphocytic leukemias with chromosomal aberrations. Leuk Res
; 38 (4): 484–9.
